Innovent Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	17,345	7,508	10,052	9,163	8,377
Short-Term Investments	886.74	375.56	867.53	-	-
Trading Asset Securities	-	-	50	3.21	638.21
Cash & Short-Term Investments	18,231	7,884	10,970	9,166	9,015
Cash Growth	131.25%	-28.13%	19.68%	1.67%	11.01%
Accounts Receivable	1,714	1,184	1,006	575.27	968.41
Receivables	1,714	1,184	1,006	575.27	975.91
Inventory	1,302	822.17	968.09	1,429	1,347
Other Current Assets	766.31	382.52	484.38	336.52	212.4
Total Current Assets	22,013	10,273	13,428	11,507	11,551
Property, Plant & Equipment	5,441	5,647	4,656	3,826	3,090
Long-Term Investments	7,860	3,901	794.09	630.2	417.26
Other Intangible Assets	1,534	307.48	27.79	30.05	19.75
Long-Term Deferred Charges	99.82	975.12	1,242	1,168	752.45
Other Long-Term Assets	399.11	499.02	478.64	427.63	412.07
Total Assets	37,348	21,603	20,627	17,589	16,244
Accounts Payable	494.59	357.68	372.55	325.62	195.05
Accrued Expenses	-	2,739	1,962	1,517	1,678
Current Portion of Long-Term Debt	789.17	405.1	1,195	888	365
Current Portion of Leases	11.03	8.83	25.18	26.39	22.27
Current Income Taxes Payable	-	75.84	194.05	3.3	60.59
Current Unearned Revenue	2,312	256.41	416.17	434.91	355.51
Other Current Liabilities	4,780	525.53	312.16	303.71	374.05
Total Current Liabilities	8,387	4,369	4,477	3,499	3,050
Long-Term Debt	1,990	2,412	2,327	2,215	2,023
Long-Term Leases	25.98	4.76	73.42	98.68	86.39
Long-Term Unearned Revenue	6,946	1,215	960.05	883.28	753.27
Other Long-Term Liabilities	643.01	483.82	262.71	162.31	0.34
Total Liabilities	17,992	8,485	8,100	6,859	5,913
Common Stock	0.12	0.11	0.11	0.11	0.1
Additional Paid-In Capital	-	27,723	27,324	24,706	22,494
Retained Earnings	-	-15,906	-15,768	-14,740	-12,560
Comprehensive Income & Other	19,356	1,301	970.54	763.86	397.02
Total Common Equity	19,356	13,118	12,528	10,730	10,330
Shareholders' Equity	19,356	13,118	12,528	10,730	10,330
Total Liabilities & Equity	37,348	21,603	20,627	17,589	16,244
Total Debt	2,816	2,831	3,621	3,229	2,497
Net Cash (Debt)	15,416	5,053	7,349	5,938	6,518
Net Cash Growth	205.10%	-31.25%	23.77%	-8.91%	-5.73%
Net Cash Per Share	8.85	3.10	4.71	3.98	4.48
Filing Date Shares Outstanding	1,712	1,638	1,622	1,534	1,462
Total Common Shares Outstanding	1,712	1,638	1,622	1,534	1,462
Working Capital	13,627	5,904	8,951	8,008	8,501
Book Value Per Share	11.31	8.01	7.72	6.99	7.07
Tangible Book Value	17,822	12,810	12,500	10,700	10,311
Tangible Book Value Per Share	10.41	7.82	7.71	6.97	7.05
Buildings	-	1,702	402.67	402.46	389.73
Machinery	-	3,133	4,795	2,523	1,420
Construction In Progress	-	1,339	6.18	1,139	1,293
Leasehold Improvements	-	426.63	121.82	107.66	106.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.